Skip to main content

Phase 3 Start

NVO: Phase3_Start: Efficacy and Safety of Zenagamtide s.c. Once-weekly in Asian Participants With Overweight or Obesity (AMAZE 13)

January 7, 2027. BioSniper AI can trace the company-impact path without requiring you to write the research question.

Event date
January 7, 2027
Company
Novo Nordisk A/S (NVO)
BioSniper AIPage evidence connected

Prepared research question

What could this event change, and which evidence should be watched next?

Run cited research

Traceable citations · Unknowns marked

Phase 3 Start

Phase3_Start: Efficacy and Safety of Zenagamtide s.c. Once-weekly in Asian Participants With Overweight or Obesity (AMAZE 13)

NVO overview →

Other upcoming events for NVO

Phase 3 StartPhase3_Start: Efficacy and Safety of Zenagamtide s.c. Once-weekly Compared to Semaglutide s.c. Once-weekly in Participants With Obesity (AMAZE 7)